The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 38%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (3 analysts) rates it buy, with a mean price target of $27. It reported earnings in this window, a natural checkpoint for the thesis.
Barclays plc ADR BCS
Outside both standards
An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Barclays PLC provides various financial services in the United Kingdom, Europe, the Americas, Africa, the Middle East, and Asia.
read at $27.91
Barclays plc ADR holds its Markup at $27.91.
- PHPhase · the trend structure carries the Markup label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · does not pass the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 1 days |
| Price | $27.91 |
| Valuation | 12.03 trailing · 8.22 forward price to earnings |
| Values screen | FAIL · score 30.0 |
| Beta | 0.88 |
The opportunity · what the numbers say it is worth
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
| Revenue growth | 3.90% |
| Profit margin | 26.77% |
| Analyst consensus | Buy · 4 covering |
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
The values screen, explained · five checks, plain English
This company is excluded by both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. It fails on both:
Used by most halal investing apps ✗ DOES NOT PASS
The one Titan applies ✗ DOES NOT PASS
Why it fails. The problem is its excluded industry: banks - diversified. Because both standards agree on this, it is a clear exclusion, not a borderline case.
What these two standards are, and how they differ →
- Business activity Excluded industry: Banks - Diversified Fail
- Debt load Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. Fail
- Interest-bearing cash Interest-bearing cash and securities are of assets, above the one-third limit. Fail
- Receivables Money owed to the company is of assets, above the 49% limit. Fail
- Revenue purity of revenue comes from non-compliant sources, over the 5% line. Fail
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
The business, in plain words · what the numbers mean
Barclays looks cheap yet ethics force a pass
Barclays moves cash for millions of British households and corporates every day, from high street accounts to investment banking deals across four continents. We pass on this name for one clear reason that has nothing to do with the numbers. It fails our ethical screen because diversified banks sit on the excluded list.
Revenue edges up only 4% a year while margins sit at 27% and return on equity reaches 10% behind a narrow moat. The shares trade at 8.2 times forward earnings with an 18% margin of safety to our fair value, and analysts rate the stock a buy, yet the ethical screen overrides any surface appeal.
Risk sits in the cyclical swings of banking earnings where low multiples often signal peak profits rather than bargains, plus regulatory and currency pressures that hit global operations hard. Analysis, not advice.
| Forward P/E | 8.2x expensive even after accounting for its growth |
| Trailing P/E | 12.0x reasonably valued |
| Revenue growth | 3.9% slow but positive growth |
| Profit margin | 26.8% healthy profit margins |
| Return on equity | 9.6% a modest return on shareholder capital |
| Beta | 0.88 steadier than the market |
| Market cap | $94.1B |
| Employees | 93,000 |
The risks · The things to watch: its business and earnings are exposed to United Kingdom and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Latest news · what the market is reading on BCS
- › Barclays (LSE:BARC) Stock May Trade At A 48% Discount As Returns On Equity Hold Simply Wall St. · 14d ago
- › Barclays (LSE:BARC) Refreshes Leadership Ranks, Is The Stock Still Cheap? Simply Wall St. · 14d ago
- › ConocoPhillips Joins US Firms Vowing $60 Billion for Iraqi Deals Bloomberg · 15d ago
- › European Equities Traded in the US as American Depositary Receipts Decline Friday MT Newswires · 15d ago
- › Neglected Quant Safety Trade Makes a Comeback as AI Risks Rise Bloomberg · 15d ago
Headlines from third-party outlets, linked for reference — not our reporting, not advice.
Related securities · others in BCS's space worth a look
Screened names in the same industry · explore each on its own page.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 38%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (3 analysts) rates it buy, with a mean price target of $27. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 38%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (3 analysts) rates it buy, with a mean price target of $27. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 38%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (3 analysts) rates it buy, with a mean price target of $27. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 38%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (3 analysts) rates it buy, with a mean price target of $27. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 38%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (3 analysts) rates it buy, with a mean price target of $27. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 38%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (3 analysts) rates it buy, with a mean price target of $27. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 9.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 38%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (3 analysts) rates it buy, with a mean price target of $27. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 38%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (3 analysts) rates it buy, with a mean price target of $27.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $23.17 | +2.6% | · | $1,026 | +2.6% |
| 2 months | $23.73 | +0.2% | · | $1,002 | +0.2% |
| 3 months | $20.89 | +13.8% | · | $1,138 | +13.8% |
| 6 months | $23.90 | -0.6% | $0.31 | $1,007 | +0.7% |
| 1 year | $17.23 | +37.9% | $0.47 | $1,406 | +40.6% |
| 2 years | $10.51 | +126.2% | $0.89 | $2,346 | +134.6% |
| 3 years | $7.13 | +233.4% | $1.30 | $3,516 | +251.6% |
| 5 years | $8.65 | +174.7% | $1.98 | $2,975 | +197.5% |
Historical returns from market close data. Past performance does not guarantee future results.